Novocure: Phase 3 Trial In Platinum-resistant Ovarian Cancer Fails To Meet Main Goal; Stock Down
Novocure (NVCR) said Monday that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival at the final analysis. In Monday pre-market trade, NVCR was trading at $17.51 down $12.26 or 41.18%. According to the company, Patients randomized […]
Read more